## Björn Brücher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4277582/publications.pdf

Version: 2024-02-01

			109137	Š	91712
	86	4,973	35		69
	papers	citations	h-index		g-index
Ī					
	0.0	0.6	0.6		6062
	96	96	96		6062
	all docs	docs citations	times ranked		citing authors

#	Article	lF	CITATIONS
1	Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World. Annals of Surgery, 2001, 234, 360-369.	2.1	452
2	Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment. Journal of Clinical Oncology, 2004, 22, 900-908.	0.8	448
3	Early Esophageal Cancer. Annals of Surgery, 2005, 242, 566-575.	2.1	399
4	Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography. Annals of Surgery, 2001, 233, 300-309.	2.1	340
5	IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunology, Immunotherapy, 2009, 58, 153-157.	2.0	281
6	Cell-Cell Communication in the Tumor Microenvironment, Carcinogenesis, and Anticancer Treatment. Cellular Physiology and Biochemistry, 2014, 34, 213-243.	1.1	170
7	Achalasia and Esophageal Cancer: Incidence, Prevalence, and Prognosis. World Journal of Surgery, 2001, 25, 745-749.	0.8	149
8	Tumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing Theories. Journal of Cancer, 2013, 4, 84-95.	1.2	146
9	18F-FDG-PET/CT to Select Patients with Peritoneal Carcinomatosis for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2009, 16, 1295-1303.	0.7	141
10	Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling. Cancer Research, 2007, 67, 8615-8623.	0.4	133
11	The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer, 2006, 106, 2119-2127.	2.0	131
12	Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. International Journal of Cancer, 2010, 126, 1513-1520.	2.3	121
13	Early Detection of Colorectal Cancer Recurrence in Patients Undergoing Surgery with Curative Intent: Current Status and Challenges. Journal of Cancer, 2014, 5, 262-271.	1.2	110
14	Effort, safety, and findings of routine preoperative endoscopic evaluation of morbidly obese patients undergoing bariatric surgery. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 1996-2001.	1.3	102
15	Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC–-Overview and Basics. Cancer Investigation, 2012, 30, 209-224.	0.6	84
16	Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer, 2001, 92, 2228-2233.	2.0	78
17	Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer. Journal of Cancer, 2014, 5, 3-24.	1.2	78
18	Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. Abdominal Imaging, 2013, 38, 64-71.	2.0	75

#	Article	IF	CITATIONS
19	The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - a Comprehensive review. Journal of Cancer, 2013, 4, 281-295.	1.2	70
20	Somatic Mutation Theory - Why it's Wrong for Most Cancers. Cellular Physiology and Biochemistry, 2016, 38, 1663-1680.	1.1	65
21	Current Approaches and Challenges for Monitoring Treatment Response in Colon and Rectal Cancer. Journal of Cancer, 2014, 5, 31-43.	1.2	64
22	Esophageal cancer: patient evaluation and pre-treatment staging. Surgical Oncology, 2001, 10, 103-111.	0.8	63
23	PGK1 a Potential Marker for Peritoneal Dissemination in Gastric Cancer. Cellular Physiology and Biochemistry, 2008, 21, 429-436.	1.1	63
24	Significance of Infectious Agents in Colorectal Cancer Development. Journal of Cancer, 2013, 4, 227-240.	1.2	62
25	Transient Lower Esophageal Sphincter Relaxation in Morbid Obesity. Obesity Surgery, 2009, 19, 595-600.	1.1	61
26	Anorectal Malignant Melanoma: Extensive 45-Year Review and Proposal for a Novel Staging Classification. Journal of the American College of Surgeons, 2013, 217, 324-335.	0.2	59
27	Treatment of acute abdominal pain in the emergency room: A systematic review of the literature. European Journal of Pain, 2014, 18, 902-913.	1.4	50
28	COVID-19: Pandemic surgery guidance. 4open, 2020, 3, 1.	0.1	48
29	Future Directions for the Early Detection of Colorectal Cancer Recurrence. Journal of Cancer, 2014, 5, 272-280.	1.2	45
30	Prognostic Factors in Resected Primary Small Bowel Tumors. Digestive Surgery, 1998, 15, 42-51.	0.6	44
31	The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. British Journal of Cancer, 2007, 97, 1404-1408.	2.9	42
32	Phosphoglycerate Kinase 1 Promoting Tumor Progression and Metastasis in Gastric Cancer - Detected in a Tumor Mouse Model Using Positron Emission Tomography/Magnetic Resonance Imaging. Cellular Physiology and Biochemistry, 2010, 26, 147-154.	1.1	40
33	Future Directions for Monitoring Treatment Response in Colorectal Cancer. Journal of Cancer, 2014, 5, 44-57.	1.2	40
34	Serum-Based DNA Methylation Biomarkers in Colorectal Cancer: Potential for Screening and Early Detection. Journal of Cancer, 2013, 4, 210-216.	1.2	38
35	VEGF-C Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus. World Journal of Surgery, 2007, 31, 1768-1772.	0.8	35
36	Response to Preoperative Therapy in Upper Gastrointestinal Cancers. Annals of Surgical Oncology, 2009, 16, 878-886.	0.7	33

#	Article	IF	CITATIONS
37	Hypermethylation ofhMLH1,HPP1,p14ARF,p16INK4A and APC in primary adenocarcinomas of the small bowel. International Journal of Cancer, 2006, 119, 1298-1302.	2.3	32
38	Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. British Journal of Cancer, 2008, 99, 1020-1026.	2.9	31
39	Peritoneal carcinomatosis: comparison of dynamic contrast-enhanced magnetic resonance imaging with surgical and histopathologic findings. Abdominal Radiology, 2012, 37, 834-842.	1.0	31
40	Multichannel Intraluminal Impedance Measurement of Gastroesophageal Reflux in Patients with Different Stages of Morbid Obesity. Obesity Surgery, 2009, 19, 1522-1529.	1.1	29
41	Squamous cell carcinoma and Zenker diverticulum. Ecological Management and Restoration, 2007, 20, 75-78.	0.2	27
42	Transient Lower Esophageal Sphincter Relaxation and Esophageal Motor Response. Journal of Surgical Research, 2010, 159, 714-719.	0.8	24
43	Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbeck's Archives of Surgery, 2011, 396, 1077-1081.	0.8	23
44	Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor $\hat{l}^21$ , and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine. British Journal of Surgery, 2006, 93, 1424-1432.	0.1	22
45	Distinct Functionality of Tumor Cell–Derived Gelatinases during Formation of Liver Metastases. Molecular Cancer Research, 2008, 6, 341-351.	1.5	22
46	Potential Combination Chemotherapy Approaches for Advanced Adult-Type Soft-Tissue Sarcoma. American Journal of Clinical Dermatology, 2008, 9, 207-217.	3.3	20
47	Glomus Tumor of the Stomach Simulating a Gastrointestinal Stromal Tumor: A Case Report and Review of Literature. Case Reports in Gastroenterology, 2008, 2, 1-5.	0.3	18
48	Esophageal squamous cell carcinoma with entirely intramural growth pattern. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 862-866.	1.4	16
49	Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. International Journal of Colorectal Disease, 2009, 24, 69-77.	1.0	16
50	NF-κB signaling and crosstalk during carcinogenesis. 4open, 2019, 2, 13.	0.1	16
51	Randomized Clinical Trials for Colorectal Cancer Peritoneal Surface Malignancy. Surgical Oncology Clinics of North America, 2012, 21, 665-688.	0.6	15
52	Amelanotic Esophageal Malignant Melanoma: Case Report and Short Review of the Literature. Case Reports in Gastroenterology, 2008, 2, 224-231.	0.3	14
53	Multi-Parametric MRI-Directed Focal Salvage Permanent Interstitial Brachytherapy for Locally Recurrent Adenocarcinoma of the Prostate: A Novel Approach. Journal of Cancer, 2013, 4, 146-151.	1,2	14
54	Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. Journal of Cancer, 2013, 4, 172-192.	1.2	14

#	Article	IF	Citations
55	Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and $\hat{l}^21$ integrin. International Journal of Oncology, 2011, 39, 1593-600.	1.4	13
56	Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 1-3.	0.7	12
57	The predictive value of genes of the TGF- $\hat{l}^21$ pathway in multimodally treated squamous cell carcinoma of the esophagus. International Journal of Colorectal Disease, 2010, 25, 515-521.	1.0	11
58	No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Molecular Carcinogenesis, 2006, 45, 349-352.	1.3	10
59	Local Peritonectomy Highly Attracts Free Floating Intraperitoneal Colorectal Tumour Cells in a Rat Model. Cellular Physiology and Biochemistry, 2009, 23, 371-378.	1.1	10
60	Patients at Risk for Peritoneal Surface Malignancy of Colorectal Cancer Origin: The Role of Second Look Laparotomy. Journal of Cancer, 2013, 4, 262-269.	1.2	10
61	Chronic inflammation evoked by pathogenic stimulus during carcinogenesis. 4open, 2019, 2, 8.	0.1	10
62	Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World Journal of Gastroenterology, 2012, 18, 2061.	1.4	10
63	Intramural esophageal hematoma after cardioversion. Ecological Management and Restoration, 1997, 10, 225-228.	0.2	8
64	Science belongs to no oneâ€"and to everyone. 4open, 2018, 1, E1.	0.1	8
65	Eicosanoids in carcinogenesis. 4open, 2019, 2, 9.	0.1	8
66	Synchronous adenocarcinoma of the lung and neuroendocrine carcinoma of the ileum. International Journal of Colorectal Disease, 2008, 23, 325-327.	1.0	7
67	Surgery of Colorectal Carcinoma in Patients Aged over 80. Oncology Research and Treatment, 2009, 32, 10-16.	0.8	6
68	Morbid Obesity and Subsequent Pancreatic Cancer: Pylorus-Preserving Pancreatoduodenectomy after Laparoscopic Sleeve Gastrectomy. Obesity Surgery, 2009, 19, 385-388.	1.1	6
69	Tumor suppressor gene adenomatous polyposis coli downregulates intestinal transport. Pflugers Archiv European Journal of Physiology, 2011, 461, 527-536.	1.3	6
70	Ischemic spinal cord syndrome after transthoracic esophagectomy: two cases of a rare neurologic complication. Ecological Management and Restoration, 2000, 13, 328-332.	0.2	6
71	Undervalued ubiquitous proteins. 4open, 2019, 2, 7.	0.1	6
72	Tumor response criteria: are they appropriate?. Future Oncology, 2012, 8, 903-906.	1.1	5

#	Article	IF	Citations
73	Microbiome and morbid obesity increase pathogenic stimulus diversity. 4open, 2019, 2, 10.	0.1	5
74	Transition from normal to cancerous cell by precancerous niche (PCN) induced chronic cell-matrix stress. 4open, 2019, 2, 14.	0.1	5
75	Precancerous niche (PCN), a product of fibrosis with remodeling by incessant chronic inflammation. 4open, 2019, 2, 11.	0.1	5
76	Barrett's esophagus: treatments of adenocarcinomas I. Annals of the New York Academy of Sciences, 2011, 1232, 248-264.	1.8	4
77	Colorectal cancer stem cells as biomarkers: Where it all starts?. Journal of Surgical Oncology, 2013, 107, 791-793.	0.8	2
78	Non-acid Gastroesophageal Reflux Measured Using Multichannel Intraluminal Impedance in Older Patients. Journal of Gastrointestinal Surgery, 2010, 14, S17-S23.	0.9	1
79	Barrett's esophagus: treatments of adenocarcinomas II. Annals of the New York Academy of Sciences, 2011, 1232, 265-291.	1.8	1
80	Application of Laser Microdissection and Quantitative PCR to Assess the Response of Esophageal Cancer to Neoadjuvant Chemo-Radiotherapy. Methods in Molecular Biology, 2011, 755, 197-202.	0.4	1
81	Synopsis: Special Issue on "Disruption of signaling homeostasis induced crosstalk in the carcinogenesis paradigm Epistemology of the origin of cancer― 4open, 2019, 2, 28.	0.1	1
82	Initiative on #4openScienceStandsForUkraine scientists and students. 4open, 2022, 5, E2.	0.1	1
83	Prelude and premise to the special issue: disruption of homeostasis-induced signaling and crosstalk in the carcinogenesis paradigm "Epistemology of the origin of cancer― 4open, 2019, 2, 6.	0.1	O
84	Metformin alters signaling induced crosstalk and homeostasis in the carcinogenesis paradigm "Epistemology of the origin of cancer― 4open, 2019, 2, 12.	0.1	0
85	In memoriam Professor Dr. Philipp A. Schnabel (1953–2021). 4open, 2022, 5, 7.	0.1	0
86	War against Ukraine: Humanitarian aid and how much morality can science bear. 4open, 2022, 5, E3.	0.1	0